Network With More Than 50 Healthcare VC firms at MedCity INVEST 2024!
The conference is the premier boutique healthcare investment event in the U.S.
This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
Rush Launches Program to Scale RPM for Chronic Conditions Management
Chicago-based Rush University System for Health recently struck a partnership with Cadence — the health system is beginning an RPM pilot using the startup's technology platform and clinicians. Rush will enroll Medicare and Medicaid patients who have one or more of the following chronic conditions: hypertension, congestive heart failure and type 2 diabetes.
A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes
CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.
ASCO Recap: Multiple Myeloma Moves, ADC Advances & Brain Cancer Progress
During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
How Data for ImmunoGen Drug Could Change the Way Doctors Treat Ovarian Cancer
In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.
In Key Study, Servier Drug Delays Brain Cancer in Patients With Few Treatment Options
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
At ASCO, BioNTech Shows Encouraging Data for Drug That Led to $200M Deal
BioNTech and OncoC4 reported Phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. Earlier this year, the German company inked a deal to share in the development of the drug in various types of solid tumors.
presented by
How Hospitals Are Reducing Gun Violence, Protecting Patients and Staff
Hospitals are places of healing, but they have also become sites of gun violence. A panel at the MedCity News INVEST conference discussed the ways hospitals can reduce threats and de-escalate situations before they become violent.
Where Cell Therapies Are Going Next, and How Insurers Are Getting Ready
Multiple efforts are underway to improve cell therapies for cancer. During the MedCity News INVEST conference in Chicago, a panel discussed the future of cell therapies and what the industry doing to manage the financial risks of these new treatments.
Health Tech Startups Show Stakeholders How Digital Solutions Can Offer ROI
A panel during the MedCity News INVEST conference discussed what digital health technologies need to do to demonstrate return on investment for payers, providers, and other stakeholders.
Which Health Tech Startups Are Competing at MedCity INVEST?
Healthcare startups focused on solutions for payers and hospitals as well as consumers and employers will compete in the Pitch Perfect contest at MedCity INVEST May 22-24 in Chicago. Register today!
presented by
MedCity INVEST Spotlight: Get Ready for the Canadian Healthcare Startup Showcase
Five companies will take part in the showcase with technologies addressing mental health, care coordination, aging in place, physical therapy and more. Register for INVEST, scheduled for May 22-24, at the Ritz Carlton in Chicago!